Related Experiment Video

Updated: Aug 9, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 19, 2013

Signal transduction inhibition: results from phase I clinical trials in chronic myeloid leukemia

B Druker1

  • 1Department of Medicine, Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, OR 97201, USA.

Seminars in Hematology
|August 30, 2001
PubMed

Insights

The tyrosine kinase inhibitor imatinib mesylate demonstrated significant antileukemic activity in chronic myeloid leukemia (CML) patients. This targeted therapy achieved high rates of hematologic remission and cytogenetic response, offering a new treatment option.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Imatinib mesylate (formerly STI571) is a tyrosine kinase inhibitor.
  • Preclinical studies indicated significant antileukemic activity and minimal toxicity.

Purpose of the Study:

  • To evaluate the safety and efficacy of imatinib mesylate in a phase I clinical trial.
  • To assess its activity in patients with chronic myeloid leukemia (CML) who failed prior treatments.

Main Methods:

  • Phase I clinical trial design.
  • Administration of imatinib mesylate to patients with CML.
  • Monitoring of hematologic and cytogenetic responses.

Main Results:

  • 98% of chronic phase CML patients achieved hematologic remission.
  • Cytogenetic responses were observed with prolonged therapy.
  • Activity was also noted in CML blast crisis and Philadelphia chromosome-positive acute lymphocytic leukemia (Ph+ ALL).

Conclusions:

  • Imatinib mesylate shows significant efficacy in treating chronic myeloid leukemia.
  • It offers a viable therapeutic option for patients with CML and Ph+ ALL.
  • Ongoing studies aim to optimize imatinib mesylate treatment strategies.

More Related Videos

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze the...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...